Background and Purpose-Several lines of evidence support the involvement of mannose-binding lectin (MBL) in stroke brain damage. The lectin pathway of the complement system facilitates thrombin activation and clot formation under certain experimental conditions. In the present study, we examine whether MBL promotes thrombosis after ischemia/ reperfusion and influences the course and prognosis of ischemic stroke. Methods-Middle cerebral artery occlusion/reperfusion was performed in MBL-deficient (n=85) and wild-type (WT; n=83) mice, and the brain lesion was assessed by MRI at days 1 and 7. Relative cerebral blood flow was monitored up to 6 hours after middle cerebral artery occlusion with laser speckle contrast imaging. Fibrin(ogen) was analyzed in the brain vasculature and plasma, and the effects of thrombin inhibitor argatroban were evaluated to assess the role of MBL in thrombin activation. Results-Infarct volumes and neurological deficits were smaller in MBL knockout mice than in WT mice. Relative cerebral blood flow values during middle cerebral artery occlusion and at reperfusion were similar in both groups, but decreased during the next 6 hours in the WT group only. Also, the WT mice showed more fibrin(ogen) in brain vessels and a better outcome after argatroban treatment. In contrast, argatroban did not improve the outcome in MBL knockout mice. Conclusions-MBL promotes brain damage and functional impairment after brain ischemia/reperfusion in mice. These effects are secondary to intravascular thrombosis and impaired relative cerebral blood flow during reperfusion. Argatroban protects WT mice, but not MBL knockout mice, emphasizing a role of MBL in local thrombus formation in acute ischemia/reperfusion. (Stroke. 2014;45:00-00.)
1
T he complement system is activated in stroke 1 and is regarded as a detrimental factor contributing to worsen the outcome. 2, 3 The complement system is not only a potent ancestral innate immune defense against invading microbes, but it is also an efficient tool promoting clearance of damaged host cells. 4 Complement can be activated through the classical, alternative, and lectin pathways that all culminate in the formation of a lytic pore in cell membranes, known as the membrane attack complex, and the production of proinflammatory small protein fragments called anaphylotoxins C3a, C5a, and C4a. 5 Blockade of C3a [6] [7] [8] and C5a 8, 9 receptors is protective against ischemia/reperfusion in animals.
The classical pathway involves IgM or IgG1 antibodies attaching to the C1q complex, which is expressed in ischemic neurons.
10 C1-inhibitor, a naturally occurring acute phase protein, is protective against ischemia/reperfusion in experimental models.
11-14 C1-inhibitor not only blocks the classical pathway but also prevents the activation of the lectin pathway, among other effects. 15 Notably, human recombinant C1-inhibitor selectively binds to mannose-binding lectin (MBL), and this mechanism is thought to mediate its protective effects in brain ischemia/reperfusion. 16 Several lines of experimental [17] [18] [19] and clinical 17, 20 evidence support that the MBL pathway exacerbates stroke brain damage. MBL knockout (KO) mice showed reduced brain damage after ischemia, and protection was lost after the administration of recombinant MBL. 17 The complement and the coagulation systems crossinteract at several molecular steps. 21, 22 Proteins of the lectin pathway can induce thrombus formation through thrombin activation, [23] [24] [25] [26] [27] thus exacerbating brain damage after ischemia/ reperfusion. [28] [29] [30] In this study, we evaluated the role of MBL in thrombus formation and whether this interaction is involved in brain damage after ischemia/reperfusion in mice.
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Methods
An extended version of methods can be found in the online-only Data Supplement.
Animal Work
Animal work was undertaken with approval of the Ethical Committee of the University of Barcelona and in compliance with the Spanish law. Adult (3-4-month-old), male wild-type (WT) and MBL KO mice 31 in the C57BL/6J background were used.
17

Brain Ischemia/Reperfusion
Ischemia was produced by intraluminal 90-minute occlusion of the right middle cerebral artery (MCAO) in WT (n=83) and MBL KO (n=85) mice. Cerebral perfusion was assessed with laser Doppler flowmetry (Perimed AB, Järfälla, Sweden). A neurological score ranging from 0 (no deficit) to 20 (maximal deficit) was performed at days 1 and 7 after MCAO.
MRI Studies
MRI was performed in a 7.0-T BioSpec animal scanner (Bruker BioSpin, Ettlingen, Germany). T2 relaxometry maps were acquired at day 1 or at days 1 and 7, and images were analyzed blinded to genotype.
Pharmacological Treatment
An osmotic pump containing argatroban (#PI-146-0050; Enzo Life Sciences; 5 μg/kg per minute for 24 hours) or vehicle (saline containing DMSO) was implanted intraperitoneally before 90-minute MCAO. One-millimeter-thick brain sections obtained at 24 hours were stained with 1% 2,3,5-triphenyltetrazolium chloride (TTC). Infarct volume with edema correction was measured in a blinded fashion.
Optical Imaging of Cerebral Blood Flow
Relative cerebral blood flow (rCBF) was studied by laser speckle flowmetry (LSF) in ischemic and sham-operated mice. A custom LSF system allowed measuring rCBF in regions of interest 
ELISA Immunoassay
Plasma fibrinogen concentration (collected in citrate) was analyzed by ELISA (#ab108844; Abcam, Cambridge, United Kingdom).
Immunofluorescence
Mice were intracardially perfused with saline followed by paraformaldehyde 24 hours after MCAO. Immunofluorescence was performed with FITC-conjugated fibrinogen antibody (#F0111; Dakocytomation, Glostrup, Denmark; 1:100) and antiglucose transporter-1 (Glut-1) antibody (#AB1340; Merck Millipore, Billerica, MA; 1:200). Fibrin(ogen)-positive blood vessels were counted in a blinded fashion.
Western Blotting
Mice were intracardially perfused with saline 24 hours after MCAO, and ipsilateral and contralateral tissue was dissected out. Cortex and striatum were obtained separately (n=6 per genotype and region). An antibody against native fibrinogen (#PAB13593; Abnova Corporation, Taipei, Taiwan) diluted 1:1000 was used. Antiactin antibody (#A1978; Sigma-Aldrich Química, Madrid, Spain) diluted 1:500 000 was the loading control. The ratio between fibrinogen and actin band intensities was calculated.
Statistical Analyses
Differences between genotypes were assessed with Student t test or Mann-Whitney test after testing for normality (KolmogorovSmirnov test). Two-way ANOVA was used for comparisons by genotype and treatment, brain hemisphere, or time. 
Results
General Information About Animals Used in This Study
MBL KO Mice Had Smaller Infarct Volumes and Neurological Deficits Compared With WT Mice
In a previous study, we found smaller infarct volumes in MBL KO than in WT mice, as assessed during postmortem with TTC. 17 Here we aimed to validate these findings in larger cohorts of mice. MRI lesion volume was evaluated at 24 hours in WT (n=36) and MBL KO (n=36) mice ( Figure 1A and 1B) . The reduction (mean±SD) in cortical perfusion after MCAO, as assessed with laser Doppler flowmetry, was 82±10% in WT group and 81±9% in MBL KO group. The MRI lesion volume was significantly smaller (P<0.01; Student t test) in MBL KO mice ( Figure 1C) , which also showed better (lower) neurological scores compared with WT mice (P<0.001; Mann-Whitney test; Figure 1D ).
To find out whether the early beneficial effect of MBL deficiency persisted at later time points, mice received a second MRI scan at day 7 (17 WT and 19 MBL KO mice; Figure 2A ). Mortality increased similarly from day 1 to day 7 in MBL KO (37%) and WT (47%) groups (χ 2 =0.38). Infarct volumes at 24 hours were higher in mice that died before day 7 than in mice that survived the 7-day study period ( Figure 2B and 2C). Post hoc analysis showed that the genotype effect on infarct volume was statistically significant at day 1 (P<0.05) but only showed a statistical trend (P=0.08) at day 7. The neurological scores were better in MBL KO mice than in WT mice at day 1 (P<0.001) and day 7 (P<0.05).
CBF at Reperfusion Was Improved in MBL KO Mice Versus WT Mice
We studied rCBF by laser Doppler and LSF in additional groups of ischemic (n=5 per genotype) and sham-operated (n=3 per genotype) mice. The laser Doppler measure (percentage of baseline) obtained during the first 30 minutes of MCAO was (mean±SD) 15.0±6.1% in WT group and 16.4±6.3% in MBL KO group (P=0.73). In the same mice, LSF ( Figure 3A ) was measured at different time points ( Figure 3B ). LSF measurement of rCBF (expressed as percentage of basal rCBF) in MCA ROI during MCAO was (mean±SD) 10.8±4.7% for WT group and 17.0±10.5% for MBL KO group (P=0.27). At reperfusion, rCBF recovered to a similar extent in MBL KO and WT mice ( Figure 3C ). However, as time progressed, rCBF decreased in WT group but not in MBL KO group ( Figure 3C ). Two-way ANOVA by genotype and time showed a significant genotype effect (P<0.05). In contrast, rCBF in the outside ROI of the ipsilateral hemisphere and in the corresponding (mirror) contralateral ROIs ( Figure 3C ) was similar for both genotypes. Nevertheless, a tendency toward contralateral CBF reduction was observed after ischemia in WT mice. This has been previously described using positron emission tomography and single photon emission CT 32 and might be related to decreases in contralateral activity because of depressed transcallosal neural connections. In sham-operated mice, rCBF values in these ROIs did not differ between WT and KO mice and were stable over time ( Figure 3D ). To discard overt genotype differences in cerebrovascular anatomy, carbon black ink was perfused intravascularly in control mice of both genotypes (n=3 per group). Visual inspection of postmortem brain and quantification of anastomoses between the MCA and the anterior carotid artery did not show genotype differences ( Figure I in the online-only Data Supplement).
MBL Deficiency Reduced Deposition of Fibrin(ogen) in Blood Vessels of Ischemic Tissue
The presence of fibrinogen increased in ischemic tissue of WT mice at 24 hours, as assessed by Western blotting ( Figure 4A ). This effect was significantly attenuated in cortex (P<0.01; Figure 4A ) and striatum (P<0.05; not shown) of MBL KO mice (n=6 per genotype and region). Also, MBL KO mice (n=6) showed less fibrin(ogen) immunopositive vessels after ischemia ( Figure 4B ; P<0.05) compared with WT mice (n=6) in cortex (not shown) and striatum ( Figure 4B and 4C) . However, plasma fibrinogen increased after ischemia in both genotypes ( Figure 4D ).
Argatroban Reduced Infarct Volume and Ameliorated Neurological Deficit in WT Mice But Not in MBL KO Mice
Because the lectin pathway can induce thrombin activation, 24, 33 we examined whether thrombin was involved in the detrimental effects of MBL by treating the mice with the direct thrombin inhibitor argatroban and measuring infarct volume at 24 
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hours ( Figure 5A and 5B). After MCAO, the reduction in cortical perfusion (mean±SD) as assessed by laser Doppler was 79±10% in the vehicle/WT group, 85±6% in the argatroban/ WT group, 87±6% in the vehicle/MBL KO group, and 81±8% in the argatroban/MBL KO group (P=0.15). The mice treated with argatroban (n=11) showed smaller infarct volumes and better neurological scores (P<0.05) compared with the mice receiving the vehicle (n=10; Figure 5C and 5D), in agreement with previous reports. 28, 29 In contrast, argatroban was not beneficial in MBL KO mice (n=8 per treatment group; Figure 5C and 5D). This finding suggested that the MBL pathway promoted local thrombin activation during reperfusion.
Discussion
The present study reports that MBL exacerbates acute ischemic damage by promoting local prothrombotic events in the brain vasculature hampering blood flow reperfusion. In WT mice, rCBF recovery at reperfusion was followed by progressive rCBF reductions and fibrin(ogen) deposition in brain vasculature. These effects might be attributable to secondary thrombotic events that can occur after local activation of the coagulation cascade during reperfusion. 34 Regardless of similar increments in circulating levels of fibrinogen after acute stroke in WT and KO mice, we observed less local vessel fibrin(ogen) in ischemic tissue of MBL KO mice. Moreover, a significant reduction in infarct volume and greater improvement in functional outcome were seen after administering the thrombin inhibitor argatroban in WT mice only. This finding further attested to the clinical relevance of the local crosstalk between the lectin pathway of complement activation and thrombin-dependent secondary thrombosis in ischemia/reperfusion injury in mice.
Several molecular interactions between the coagulation and complement cascades illustrate the complex crosstalk between these protease systems. 21 Proteins of the lectin pathway can activate the coagulation cascade, as shown in vitro [23] [24] [25] [26] and in vivo. 27 MBL has no enzymatic activity and needs to bind the MBL-associated serine proteases (MASP). MBL binding to MASP-2 activates the complement by cleavage of C4 and C2. 35 MASP-2 can cleave prothrombin and form thrombin, 24 and MASP-1 promotes the formation of crosslinked fibrin. 36 Also, the activation of MASPs can induce the formation of fibrin clots, 25 and human MBL-MASPs complex can mimic thrombin and initiate coagulation. 33 The procoagulant effects of lectin pathway proteins may contribute to eliminating invading pathogens by sequestering them though local activation of the coagulation cascade preventing dissemination throughout the organism. 36 However, local prothrombotic events in injured brain vasculature may impair reperfusion and enhance brain damage after acute ischemic stroke.
Thrombin activates platelets, converts fibrinogen to a fibrin mesh, and cleaves factor XIII as well as performs other important functions in coagulation. 37 In brain ischemia, thrombin mediates severe vascular disruption and damage to the neurovascular unit. 29, 30 Accordingly, the thrombin inhibitor argatroban reduces brain injury after ischemia/reperfusion in experimental animals [28] [29] [30] and extends the therapeutic window of recombinant tissue plasminogen activator. 28 In humans, a pilot study of the combined administration of argatroban and intravenous recombinant tissue plasminogen activator showed a greater recanalization rate compared with recombinant tissue plasminogen activator alone in stroke patients with proximal intracranial arterial occlusions. 38 In the present study, argatroban protected WT mice, but not MBL KO mice, suggesting that the deleterious effect of MBL were mediated, at least in part, by thrombin activation.
Long-lasting protection was reported after pharmacologically targeting the MBL pathway, 19 and genetic MBL deficiency in humans was associated with a better stroke outcome. 17, 20 However, in a previous study, the benefits of mouse MBL deficiency in acute stroke were not sustained at day 7. 39 Here, the protection of MBL deficiency, as assessed by longitudinal MRI, was still seen at 7 days, but group differences in infarct volume were attenuated compared with those at day 1. Several components of the complement system have regulatory functions in stem cells, 40 and neural progenitors and immature neurons express receptors for complement fragments. 41 Furthermore, complement proteins can facilitate regeneration in various models of central nervous system disease. 42 Therefore, the possibility that MBL may play different roles during the recovery phase cannot be excluded.
Conclusions
The findings suggest that MBL impairs cerebral circulation at reperfusion after MCAO by promoting local intravascular thrombotic events through a mechanism involving thrombin activation. Future clinical studies in acute stroke patients assessing the value of direct thrombin inhibitors might benefit from patient stratification by their MBL genotype.
(ROI) using NIH Image--J software (http://rsb.info.nih.gov/ij). A correction for edema was made by multiplying the infarct area by the ratio of the contralateral to the ipsilateral hemisphere areas. Mice were scanned at day 1, or at day 1 and day 7, and images were analyzed blinded to genotype.
Optical Imaging of cerebral blood flow
We conducted a longitudinal study comparing relative cerebral blood flow (rCBF) changes of WT and MBL KO mice during 6 hours following MCAO (n=10; 5 mice per genotype) or sham--operation (n=6; 3 mice per genotype) using laser speckle imaging (LSF). A custom LSF system was used measuring the cortical rCBF in various brain zones: the ischemic core (MCA ROI), the surrounding region of the ipsilateral hemisphere (outside ROI), and corresponding ROIs in the contralateral hemisphere, and monitoring the evolution of the hemodynamics. A 15--min baseline was measured prior to ischemia. The initial drop in rCBF after MCAO was assessed with laser Doppler in the first 30 min of MCAO, while LSF was used to monitor rCBF during the last 30 min of MCAO, for one hour following reperfusion, at 4 and 6 hours. LSF values during MCAO were taken as 5--minute average values at the 60--minute mark of the occlusion. In order to avoid long periods of anesthesia, the mice were allowed to recover between the 2.5, 4, and 6--hour time points. The rCBF of the ipsilateral hemisphere was calculated relative to the baseline. The regions of interest were determined anatomically using a reflectance image of the ischemic mouse at 525 nm (to enhance the contrast of the vasculature). This was compared to the laser speckle contrast image of flow to determine the MCA and outside regions. For each mouse, these ROIs were placed using the location of the Bregma as a reference. Brain vascular anatomy Control mice of both genotypes (n=3 per group) were anesthetized with isoflurane and transcardially perfused with 10 mL of heparinized (10 U/mL) 0.1 M phosphate buffer (PB), pH 7.4, followed by 10 mL of a carbon black ink solution (25%) made in 6% gelatin in 0.1 M PB and maintained at 37 ºC. 1 The brain was removed and was kept in 4% paraformaldehyde in PB for 24 hours, and then washed in PB. Macroscopic pictures of ventral and dorsal views of the brain were taken with the 5.8 x magnification of a macroscope (Wild 420, Leica Microsystems) using a digital camera (DXM1200F, Nikon). Image analyses were carried out with NIH ImageJ software following a previously described procedure. 2 In brief, a line was drawn between anastomotic points of the anterior carotid artery (ACA) and the MCA. The distance between this line and the midline was calculated at 3 and 6 mm from the frontal pole of the brain. The number of ACA and MCA anastomoses was counted. Values were obtained for each hemisphere and the mean value was taken as representative of each mouse.
Pharmacological treatment
The direct thrombin inhibitor argatroban (#PI--146--0050, Enzo Life Sciences) was administered to the WT mice and the MBL--null mice. Mice were anesthetized with isoflurane as above and osmotic pumps (# 1003D, DURECT Corporation, ALZET Osmotic Pumps, Cupertino, CA, USA) filled with 100 μl of either an argatroban solution (9 mg/mL) or the vehicle solution (saline containing DMSO) were implanted intraperitoneally for 24 hours. The dose rate of argatroban was 5 μg Kg --1 min --1 . With this dosing regimen animals of both groups received 0.005 µl DMSO per min. Immediately after pump implantation the MCA was occluded for 90 min followed by reperfusion. After 24 hours, mice were anesthetized, blood samples were obtained and mice were killed. The brain was sliced in 1--mm thick sections that were stained with a solution of 1 % 2,3,5--triphenyltetrazolium chloride (TTC) in saline
